Regeneron Announces Panel Discussion at Citi's 5th Annual Biotech Day

TARRYTOWN, N.Y.,Sept. 28/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will participate in a webcast panel discussion on the topic "Eye Diseases: Novel Therapies for Wet AMD, Retinal Vein Occlusion and Diabetic Macular Edema" at Citi's 5th Annual Biotech Day onTuesday, October 5, 2010.  The panel discussion will be broadcast live at8:00 a.m. Eastern Timeand may be accessed through the Company's web site,www.regeneron.com, on the Investor Relations page.  An archived version of the presentation will be available after the live webcast throughNovember 4, 2010.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site atwww.regeneron.com.